Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Gelsi-Boyer V"" wg kryterium: Wszystkie pola


Tytuł :
Mutational analysis of the DOK2 haploinsufficient tumor suppressor gene in chronic myelomonocytic leukemia (CMML)
Autorzy :
Coppin, EAff1, Aff2, Aff3, Aff4
Gelsi-Boyer, VAff1, Aff2, Aff3, Aff4
Morelli, XAff1, Aff2, Aff3, Aff4
Cervera, NAff1, Aff2, Aff3, Aff4
Murati, AAff1, Aff2, Aff3, Aff4
Pandolfi, P PAff5, Aff6, Aff7
Birnbaum, DAff1, Aff2, Aff3, Aff4
Nunès, J AAff1, Aff2, Aff3, Aff4
Pokaż więcej
Źródło :
Leukemia. 29(2):500-502
Czasopismo naukowe
Tytuł :
Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers.
Autorzy :
Fagnan A; Unité 1170 (U1170), INSERM, Gustave Roussy, Université Paris Diderot, Villejuif, France.; Equipe Labellisée Ligue Nationale Contre le Cancer, Paris, France.
Bagger FO; University Children's Hospital Beider Basel (UKBB), Basel, Switzerland.; Department of Biomedicine, University of Basel, Basel, Switzerland.; Center for Genomic Medicine, Copenhagen University Hospital, Copenhagen, Denmark.; Swiss Institute of Bioinformatics, Basel, Basel, Switzerland.
Piqué-Borràs MR; University Children's Hospital Beider Basel (UKBB), Basel, Switzerland.; Department of Biomedicine, University of Basel, Basel, Switzerland.
Ignacimouttou C; Unité 1170 (U1170), INSERM, Gustave Roussy, Université Paris Diderot, Villejuif, France.; Equipe Labellisée Ligue Nationale Contre le Cancer, Paris, France.
Caulier A; Equipe d'Accueil (EA) 4666, Hématopoïèse et Immunologie (HEMATIM), Université de Picardie Jules Verne (UPJV), Amiens, France.; Service Hématologie Biologique, Centre Hospitalier Universitaire (CHU) Amiens, Amiens, France.
Lopez CK; Unité 1170 (U1170), INSERM, Gustave Roussy, Université Paris Diderot, Villejuif, France.; Equipe Labellisée Ligue Nationale Contre le Cancer, Paris, France.
Robert E; Unité 1170 (U1170), INSERM, Gustave Roussy, Université Paris Diderot, Villejuif, France.; Equipe Labellisée Ligue Nationale Contre le Cancer, Paris, France.
Uzan B; Unité Mixte de Recherche 967 (UMR 967), INSERM-Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA)/Direction de la Recherche Fondamentale (DRF)/Institut de Biologie François Jacob (IBFJ)/Institut de Radiobiologie Cellulaire et Moléculaire (IRCM)/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL)-Université Paris-Diderot-Université Paris-Sud, Fontenay-aux-Roses, France.
Gelsi-Boyer V; U1068 and.; UMR7258, Centre de Recherche en Cancérologie de Marseille, Centre National de la Recherche Scientifique (CNRS)/INSERM/Institut Paoli Calmettes/Aix-Marseille Université, Marseille, France.
Aid Z; Unité 1170 (U1170), INSERM, Gustave Roussy, Université Paris Diderot, Villejuif, France.; Equipe Labellisée Ligue Nationale Contre le Cancer, Paris, France.
Thirant C; Unité 1170 (U1170), INSERM, Gustave Roussy, Université Paris Diderot, Villejuif, France.; Equipe Labellisée Ligue Nationale Contre le Cancer, Paris, France.
Moll U; Institute of Molecular Oncology, University Medical Center Göttingen, Göttingen, Germany.; Department of Pathology, Stony Brook University, Stony Brook, NY.
Tauchmann S; University Children's Hospital Beider Basel (UKBB), Basel, Switzerland.; Department of Biomedicine, University of Basel, Basel, Switzerland.
Kurtovic-Kozaric A; Clinical Center of the University of Sarajevo, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
Maciejewski J; Department of Translational Hematology and Oncologic Research, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH.
Dierks C; Hämatologie, Onkologie und Stammzelltransplantation, Klinik für Innere Medizin I, Freiburg, Germany.
Spinelli O; UOC Ematologia, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy.
Salmoiraghi S; UOC Ematologia, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy.; FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.
Pabst T; Department of Oncology, Inselspital, University Hospital Bern/University of Bern, Bern, Switzerland.
Shimoda K; Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Deleuze V; IGMM, University of Montpellier, CNRS, Montpellier, France.; Université de Paris, Laboratory of Excellence GR-Ex, Paris, France.
Lapillonne H; Centre de Recherche Saint Antoine (CRSA)-Unité INSERM, Sorbonne Université/Assistance Publique-Hôpitaux de Paris (AP-HP)/Hôpital Trousseau, Paris, France.
Sweeney C; Medical Research Council Molecular Haematology Unit (MRC MHU), Biomedical Research Centre (BRC) Hematology Theme, Oxford Biomedical Research Centre, Oxford Centre for Haematology, Weatherall Institute of Molecular Medicine (WIMM), Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
De Mas V; Team 16, Hematology Laboratory, Center of Research of Cancerology of Toulouse, U1037, INSERM/Institut Universitaire du Cancer de Toulouse (IUCT) Oncopole, Toulouse, France.
Leite B; Genomic Platform, Unité Mixte de Service - Analyse Moléculaire, Modélisation et Imagerie de la maladie Cancéreuse (UMS AMMICA), Gustave Roussy/Université Paris-Saclay, Villejuif, France.
Kadri Z; Division of Innovative Therapies, UMR-1184, Immunologie des Maladies Virales, Auto-immunes, Hématologiques et Bactériennes (IMVA-HB) and Infectious Disease Models and Innovative Therapies (IDMIT) Center, CEA/INSERM/Paris-Saclay University, Fontenay-aux-Roses, France.
Malinge S; Unité 1170 (U1170), INSERM, Gustave Roussy, Université Paris Diderot, Villejuif, France.; Telethon Kids Institute, Perth Children's Hospital, Nedlands, WA, Australia.
de Botton S; Unité 1170 (U1170), INSERM, Gustave Roussy, Université Paris Diderot, Villejuif, France.; Equipe Labellisée Ligue Nationale Contre le Cancer, Paris, France.
Micol JB; Unité 1170 (U1170), INSERM, Gustave Roussy, Université Paris Diderot, Villejuif, France.
Kile B; Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia.
Carmichael CL; Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia.
Iacobucci I; Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
Mullighan CG; Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN.; Hematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN.
Carroll M; Division of Hematology and Oncology, University of Pennsylvania, PA.
Valent P; Division of Hematology and Hemostaseology, Department of Internal Medicine I and.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Bernard OA; Unité 1170 (U1170), INSERM, Gustave Roussy, Université Paris Diderot, Villejuif, France.; Equipe Labellisée Ligue Nationale Contre le Cancer, Paris, France.
Delabesse E; Team 16, Hematology Laboratory, Center of Research of Cancerology of Toulouse, U1037, INSERM/Institut Universitaire du Cancer de Toulouse (IUCT) Oncopole, Toulouse, France.
Vyas P; Medical Research Council Molecular Haematology Unit (MRC MHU), Biomedical Research Centre (BRC) Hematology Theme, Oxford Biomedical Research Centre, Oxford Centre for Haematology, Weatherall Institute of Molecular Medicine (WIMM), Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
Birnbaum D; U1068 and.; UMR7258, Centre de Recherche en Cancérologie de Marseille, Centre National de la Recherche Scientifique (CNRS)/INSERM/Institut Paoli Calmettes/Aix-Marseille Université, Marseille, France.
Anguita E; Hematology Department.; Instituto de Medicina de Laboratorio (IML), and.; Instituto de Investigación Sanitaria San Carlos, (IdISSC), Hospital Clínico San Carlos (HCSC), Madrid, Spain; and.; Department of Medicine, Universidad Complutense de Madrid (UCM), Madrid, Spain.
Garçon L; Equipe d'Accueil (EA) 4666, Hématopoïèse et Immunologie (HEMATIM), Université de Picardie Jules Verne (UPJV), Amiens, France.; Service Hématologie Biologique, Centre Hospitalier Universitaire (CHU) Amiens, Amiens, France.
Soler E; IGMM, University of Montpellier, CNRS, Montpellier, France.; Université de Paris, Laboratory of Excellence GR-Ex, Paris, France.
Schwaller J; University Children's Hospital Beider Basel (UKBB), Basel, Switzerland.; Department of Biomedicine, University of Basel, Basel, Switzerland.
Mercher T; Unité 1170 (U1170), INSERM, Gustave Roussy, Université Paris Diderot, Villejuif, France.; Equipe Labellisée Ligue Nationale Contre le Cancer, Paris, France.
Pokaż więcej
Źródło :
Blood [Blood] 2020 Aug 06; Vol. 136 (6), pp. 698-714.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Transcriptome*
Leukemia, Erythroblastic, Acute/*genetics
Neoplasm Proteins/*physiology
Transcription Factors/*physiology
Adult ; Animals ; Cell Transformation, Neoplastic/genetics ; DNA-Binding Proteins/deficiency ; DNA-Binding Proteins/genetics ; DNA-Binding Proteins/physiology ; Erythroblasts/metabolism ; Erythropoiesis/genetics ; Female ; GATA1 Transcription Factor/deficiency ; GATA1 Transcription Factor/genetics ; Gene Knock-In Techniques ; Genetic Heterogeneity ; Hematopoietic Stem Cells/metabolism ; Humans ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Inbred NOD ; Mice, Transgenic ; Middle Aged ; Mutation ; Neoplasm Proteins/genetics ; Neoplastic Stem Cells/metabolism ; Proto-Oncogene Proteins/deficiency ; Proto-Oncogene Proteins/genetics ; Proto-Oncogene Proteins/physiology ; RNA-Seq ; Radiation Chimera ; Repressor Proteins/genetics ; Repressor Proteins/physiology ; Transcription Factors/genetics ; Transcriptional Regulator ERG/genetics ; Transcriptional Regulator ERG/physiology ; Whole Exome Sequencing ; Young Adult
SCR Disease Name :
Acute erythroleukemia
Czasopismo naukowe
Tytuł :
Acute erythroid leukemias have a distinct molecular hierarchy from non-erythroid acute myeloid leukemias.
Autorzy :
Cervera N; Laboratoire d'Oncologie Prédictive, Centre de Recherche en Cancérologie de Marseille UMR1068 Inserm, Institut Paoli-Calmettes, CNRS UMR7258, Aix-Marseille Université UM105, Marseille.
Lhoumeau AC; Laboratoire d'Oncologie Prédictive, Centre de Recherche en Cancérologie de Marseille UMR1068 Inserm, Institut Paoli-Calmettes, CNRS UMR7258, Aix-Marseille Université UM105, Marseille.; Département de BioPathologie, Institut Paoli-Calmettes, Marseille.
Adélaïde J; Laboratoire d'Oncologie Prédictive, Centre de Recherche en Cancérologie de Marseille UMR1068 Inserm, Institut Paoli-Calmettes, CNRS UMR7258, Aix-Marseille Université UM105, Marseille.
Guille A; Laboratoire d'Oncologie Prédictive, Centre de Recherche en Cancérologie de Marseille UMR1068 Inserm, Institut Paoli-Calmettes, CNRS UMR7258, Aix-Marseille Université UM105, Marseille.
Murati A; Laboratoire d'Oncologie Prédictive, Centre de Recherche en Cancérologie de Marseille UMR1068 Inserm, Institut Paoli-Calmettes, CNRS UMR7258, Aix-Marseille Université UM105, Marseille.; Département de BioPathologie, Institut Paoli-Calmettes, Marseille.
Mozziconacci MJ; Département de BioPathologie, Institut Paoli-Calmettes, Marseille.
Vey N; Département d'Hématologie, Institut Paoli-Calmettes, Marseille, France.
Birnbaum D; Laboratoire d'Oncologie Prédictive, Centre de Recherche en Cancérologie de Marseille UMR1068 Inserm, Institut Paoli-Calmettes, CNRS UMR7258, Aix-Marseille Université UM105, Marseille.
Gelsi-Boyer V; Laboratoire d'Oncologie Prédictive, Centre de Recherche en Cancérologie de Marseille UMR1068 Inserm, Institut Paoli-Calmettes, CNRS UMR7258, Aix-Marseille Université UM105, Marseille.; Département de BioPathologie, Institut Paoli-Calmettes, Marseille.
Pokaż więcej
Źródło :
Haematologica [Haematologica] 2020 Jul; Vol. 105 (7), pp. e340-e342. Date of Electronic Publication: 2019 Oct 10.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Leukemia, Myeloid, Acute*/genetics
Acute Disease ; Child ; Humans
Raport
Tytuł :
Gains of EPOR and ERG genes in adult erythroleukaemia.
Autorzy :
Adélaïde J; Laboratoire d'Oncologie Prédictive, Centre de Recherche en Cancérologie de Marseille (CRCM), UMR 1068 Inserm, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille Université UM105, Marseille, France.
Cervera N; Laboratoire d'Oncologie Prédictive, Centre de Recherche en Cancérologie de Marseille (CRCM), UMR 1068 Inserm, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille Université UM105, Marseille, France.
Guille A; Laboratoire d'Oncologie Prédictive, Centre de Recherche en Cancérologie de Marseille (CRCM), UMR 1068 Inserm, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille Université UM105, Marseille, France.
Murati A; Laboratoire d'Oncologie Prédictive, Centre de Recherche en Cancérologie de Marseille (CRCM), UMR 1068 Inserm, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille Université UM105, Marseille, France.; Département de BioPathologie, Institut Paoli-Calmettes, Marseille, France.
Chaffanet M; Laboratoire d'Oncologie Prédictive, Centre de Recherche en Cancérologie de Marseille (CRCM), UMR 1068 Inserm, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille Université UM105, Marseille, France.
Mozziconacci MJ; Département de BioPathologie, Institut Paoli-Calmettes, Marseille, France.
Vey N; Hématologie, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Marseille, France.
Birnbaum D; Laboratoire d'Oncologie Prédictive, Centre de Recherche en Cancérologie de Marseille (CRCM), UMR 1068 Inserm, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille Université UM105, Marseille, France.
Gelsi-Boyer V; Laboratoire d'Oncologie Prédictive, Centre de Recherche en Cancérologie de Marseille (CRCM), UMR 1068 Inserm, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille Université UM105, Marseille, France.; Département de BioPathologie, Institut Paoli-Calmettes, Marseille, France.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2020 May; Vol. 189 (4), pp. e174-e177. Date of Electronic Publication: 2020 Mar 29.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Leukemia, Erythroblastic, Acute/*genetics
Receptors, Erythropoietin/*genetics
Adult ; Gene Dosage ; Humans ; Prognosis ; Transcriptional Regulator ERG/genetics
Raport
Tytuł :
Mutation patterns in essential thrombocythemia, polycythemia vera and secondary myelofibrosis.
Autorzy :
Wanquet A; a Laboratoire d'Oncologie Prédictive , Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille , Inserm U1068 CNRS UMR 7258 , Marseille , France.; b Aix-Marseille Université , Marseille , France.; c Département d'Hématologie , Institut Paoli-Calmettes , Marseille , France.
Courtier F; a Laboratoire d'Oncologie Prédictive , Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille , Inserm U1068 CNRS UMR 7258 , Marseille , France.; b Aix-Marseille Université , Marseille , France.
Guille A; a Laboratoire d'Oncologie Prédictive , Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille , Inserm U1068 CNRS UMR 7258 , Marseille , France.
Carbuccia N; a Laboratoire d'Oncologie Prédictive , Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille , Inserm U1068 CNRS UMR 7258 , Marseille , France.
Garnier S; a Laboratoire d'Oncologie Prédictive , Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille , Inserm U1068 CNRS UMR 7258 , Marseille , France.
Adélaide J; a Laboratoire d'Oncologie Prédictive , Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille , Inserm U1068 CNRS UMR 7258 , Marseille , France.
Gelsi-Boyer V; a Laboratoire d'Oncologie Prédictive , Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille , Inserm U1068 CNRS UMR 7258 , Marseille , France.; b Aix-Marseille Université , Marseille , France.; d Département de BioPathologie , Institut Paoli-Calmettes , Marseille , France.
Mozziconacci MJ; d Département de BioPathologie , Institut Paoli-Calmettes , Marseille , France.
Rey J; c Département d'Hématologie , Institut Paoli-Calmettes , Marseille , France.
Vey N; b Aix-Marseille Université , Marseille , France.; c Département d'Hématologie , Institut Paoli-Calmettes , Marseille , France.
Birnbaum D; a Laboratoire d'Oncologie Prédictive , Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille , Inserm U1068 CNRS UMR 7258 , Marseille , France.; b Aix-Marseille Université , Marseille , France.
Murati A; a Laboratoire d'Oncologie Prédictive , Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille , Inserm U1068 CNRS UMR 7258 , Marseille , France.; b Aix-Marseille Université , Marseille , France.; d Département de BioPathologie , Institut Paoli-Calmettes , Marseille , France.
Pokaż więcej
Źródło :
Leukemia & lymphoma [Leuk Lymphoma] 2019 May; Vol. 60 (5), pp. 1289-1293. Date of Electronic Publication: 2019 Jan 02.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Genetic Predisposition to Disease*
Mutation*
Polycythemia Vera/*genetics
Primary Myelofibrosis/*genetics
Thrombocythemia, Essential/*genetics
Biomarkers ; Genetic Association Studies ; Humans ; Kaplan-Meier Estimate ; Polycythemia Vera/diagnosis ; Polycythemia Vera/mortality ; Primary Myelofibrosis/diagnosis ; Primary Myelofibrosis/mortality ; Prognosis ; Thrombocythemia, Essential/diagnosis ; Thrombocythemia, Essential/mortality
Raport
Tytuł :
Autoimmune diseases in myelodysplastic syndrome favors patients survival: A case control study and literature review.
Autorzy :
Seguier J; Aix-Marseille Univ, APHM, Medecine Interne Hôpital de la Timone, Marseille, France.
Gelsi-Boyer V; Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Marseille, France.
Ebbo M; Aix-Marseille Univ, APHM, Medecine Interne Hôpital de la Timone, Marseille, France.
Hamidou Z; Aix-Marseille Univ, APHM, EA 3279, Département de santé publique, Marseille, France.
Charbonnier A; Institut Paoli-Calmettes, Département d'Hématologie, Marseille, France.
Bernit E; Aix-Marseille Univ, APHM, Medecine Interne Hôpital de la Timone, Marseille, France.
Durand JM; Aix-Marseille Univ, APHM, Medecine Interne Hôpital de la Timone, Marseille, France.
Harlé JR; Aix-Marseille Univ, APHM, Medecine Interne Hôpital de la Timone, Marseille, France.
Vey N; Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Marseille, France.
Schleinitz N; Aix-Marseille Univ, APHM, Medecine Interne Hôpital de la Timone, Marseille, France. Electronic address: .
Pokaż więcej
Źródło :
Autoimmunity reviews [Autoimmun Rev] 2019 Jan; Vol. 18 (1), pp. 36-42. Date of Electronic Publication: 2018 Nov 05.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Autoimmune Diseases/*etiology
Myelodysplastic Syndromes/*complications
Aged ; Autoimmune Diseases/pathology ; Case-Control Studies ; Female ; Humans ; Male ; Myelodysplastic Syndromes/mortality ; Myelodysplastic Syndromes/pathology ; Prognosis ; Prospective Studies ; Retrospective Studies ; Survival Analysis
Czasopismo naukowe
Tytuł :
Clinical Characteristics and Optimal Therapy of Acute Myeloid Leukemia with Myelodysplasia-Related Changes: A Retrospective Analysis of a Cohort of Chinese Patients.
Autorzy :
Lei Wang
Xiaoxia Chu
Jingyao Wang
Licai An
Yinghui Liu
Li Li
Junqing Xu
Pokaż więcej
Alternatywny tytuł :
Myelodisplazi İlişkili Değişiklikler Gösteren Akut Myeloid Löseminin Klinik Özellikleri ve Optimal Tedavisi: Çinli Hastalar Kohortunun Retrospektif Bir Analizi.
Źródło :
Turkish Journal of Hematology. 2021, Vol. 38 Issue 3, p188-194. 7p.
Czasopismo naukowe
Tytuł :
Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations.
Autorzy :
Martín I; Hematology Department, Hospital Clínico Universitario de Valencia, INCLIVA Research Institute, University of Valencia, Valencia, Spain.
Villamón E; Hematology Department, Hospital Clínico Universitario de Valencia, INCLIVA Research Institute, University of Valencia, Valencia, Spain.
Abellán R; Biochemistry and Molecular Pathology Department, Hospital Clínico Universitario de Valencia, INCLIVA Research Institute, Valencia, Spain.
Calasanz MJ; CIMA LAB Diagnostics, Universidad de Navarra, Pamplona, Spain.
Irigoyen A; CIMA LAB Diagnostics, Universidad de Navarra, Pamplona, Spain.
Sanz G; Hematology Department, Hospital Universitario y Politécnico La Fe, Health Research Institute Hospital La Fe, IIS La Fe, Valencia, Spain.
Such E; Hematology Department, Hospital Universitario y Politécnico La Fe, Health Research Institute Hospital La Fe, IIS La Fe, Valencia, Spain.
Mora E; Hematology Department, Hospital Universitario y Politécnico La Fe, Health Research Institute Hospital La Fe, IIS La Fe, Valencia, Spain.
Gutiérrez M; Genetics Department, Hospital Universitario Infanta Sofía, Madrid, Spain.
Collado R; Hematology Department, Consorcio Hospital General Universitario de Valencia, Research Foundation of the General University Hospital of Valencia, Valencia, Spain.
García-Serra R; Hematology Department, Consorcio Hospital General Universitario de Valencia, Research Foundation of the General University Hospital of Valencia, Valencia, Spain.
Vara M; Hematology Department, Hospital Universitario de Cruces, Barakaldo, Spain.
Blanco ML; Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Oiartzabal I; Hematology Department, Hospital de Txagorritxu, Vitoria-Gasteiz, Spain.
Álvarez S; NIMGenetics, Genómica y Medicina, Madrid, Spain.; Hematology Department, Hospital HM Sanchinarro, Madrid, Spain.
Bernal T; Hematology Department, Hospital Universidad de Asturias, IISPA, IUOPA, Oviedo, Spain.
Granada I; Hematology Department, Hospital Germans Trias i Pujol, Institut Català d'Oncologia, Josep Carreras Leukaemia Research Institute (IJC), Universidad Autónoma de Barcelona, Barcelona, Spain.
Xicoy B; Hematology Department, Hospital Germans Trias i Pujol, Institut Català d'Oncologia, Josep Carreras Leukaemia Research Institute (IJC), Universidad Autónoma de Barcelona, Barcelona, Spain.
Jerez A; Hematology Department, Hospital Universitario Morales Meseguer, Murcia, Spain.
Calabuig M; Hematology Department, Hospital Clínico Universitario de Valencia, INCLIVA Research Institute, University of Valencia, Valencia, Spain.
Diez R; Hematology Department, Hospital Universitario Miguel Servet de Zaragoza, Zaragoza, Spain.
Gil Á; Hematology Department, Hospital Universitario de Guadalajara, Guadalajara, Spain.
Díez-Campelo M; Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain.
Solano C; Hematology Department, Hospital Clínico Universitario de Valencia, INCLIVA Research Institute, University of Valencia, Valencia, Spain.; Department of Medicine, School of Medicine, University of Valencia, Valencia, Spain.
Tormo M; Hematology Department, Hospital Clínico Universitario de Valencia, INCLIVA Research Institute, University of Valencia, Valencia, Spain.
Pokaż więcej
Corporate Authors :
Spanish Group of Myelodysplastic Syndromes (GESMD)
Źródło :
British journal of haematology [Br J Haematol] 2021 Aug; Vol. 194 (4), pp. 708-717. Date of Electronic Publication: 2021 Jul 22.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology.
Autorzy :
Fitzpatrick MJ; Department of Pathology, Massachusetts General Hospital, Harvard Medical School.
Massoth LR; Department of Pathology, Massachusetts General Hospital, Harvard Medical School.
Marcus C; Foundation Medicine Inc., Cambridge, MA.
Vergilio JA; Foundation Medicine Inc., Cambridge, MA.
Severson E; Foundation Medicine Inc., Cambridge, MA.
Duncan D; Foundation Medicine Inc., Cambridge, MA.
Ramkissoon SH; Foundation Medicine Inc., Cambridge, MA.; Wake Forest Comprehensive Cancer Center and Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC.
Hasserjian RP; Department of Pathology, Massachusetts General Hospital, Harvard Medical School.
Kim AS; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston.
Sohani AR; Department of Pathology, Massachusetts General Hospital, Harvard Medical School.
Williams EA; Foundation Medicine Inc., Cambridge, MA.; Department of Pathology, Department of Dermatology, UCSF Dermatopathology Service, University of California San Francisco, San Francisco, CA.
Nardi V; Department of Pathology, Massachusetts General Hospital, Harvard Medical School.
Pokaż więcej
Źródło :
The American journal of surgical pathology [Am J Surg Pathol] 2021 Jul 01; Vol. 45 (7), pp. 895-904.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Gene Fusion*
Gene Rearrangement*
Biomarkers, Tumor/*genetics
Janus Kinase 2/*genetics
Ki-1 Antigen/*analysis
Lymphoma, Large-Cell, Anaplastic/*genetics
Lymphoma, T-Cell, Peripheral/*genetics
Adult ; Aged ; Aged, 80 and over ; Genetic Predisposition to Disease ; Humans ; Lewis X Antigen/analysis ; Lymphoma, Large-Cell, Anaplastic/enzymology ; Lymphoma, Large-Cell, Anaplastic/immunology ; Lymphoma, T-Cell, Peripheral/enzymology ; Lymphoma, T-Cell, Peripheral/immunology ; Male ; Middle Aged ; Phenotype ; Poly(A)-Binding Protein I/genetics ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Genomic analysis of myeloproliferative neoplasms in chronic and acute phases.
Autorzy :
Courtier F; Centre de Recherche en Cancérologie de Marseille, (CRCM), Inserm, U1068, CNRS UMR7258, France.; Institut Paoli-Calmettes (IPC), Département d'Oncologie Moléculaire, UM 105, Marseille, F-13284, France.; Aix-Marseille Université, UM 105, Marseille, F-13284, France.
Carbuccia N; Centre de Recherche en Cancérologie de Marseille, (CRCM), Inserm, U1068, CNRS UMR7258, France.; Institut Paoli-Calmettes (IPC), Département d'Oncologie Moléculaire, UM 105, Marseille, F-13284, France.
Garnier S; Centre de Recherche en Cancérologie de Marseille, (CRCM), Inserm, U1068, CNRS UMR7258, France.; Institut Paoli-Calmettes (IPC), Département d'Oncologie Moléculaire, UM 105, Marseille, F-13284, France.
Guille A; Centre de Recherche en Cancérologie de Marseille, (CRCM), Inserm, U1068, CNRS UMR7258, France.; Institut Paoli-Calmettes (IPC), Département d'Oncologie Moléculaire, UM 105, Marseille, F-13284, France.
Adélaïde J; Centre de Recherche en Cancérologie de Marseille, (CRCM), Inserm, U1068, CNRS UMR7258, France.; Institut Paoli-Calmettes (IPC), Département d'Oncologie Moléculaire, UM 105, Marseille, F-13284, France.
Cervera N; Centre de Recherche en Cancérologie de Marseille, (CRCM), Inserm, U1068, CNRS UMR7258, France.; Institut Paoli-Calmettes (IPC), Département d'Oncologie Moléculaire, UM 105, Marseille, F-13284, France.
Gelsi-Boyer V; Centre de Recherche en Cancérologie de Marseille, (CRCM), Inserm, U1068, CNRS UMR7258, France.; Institut Paoli-Calmettes (IPC), Département d'Oncologie Moléculaire, UM 105, Marseille, F-13284, France.; IPC, Département de Biopathologie, Marseille, UM 105, Marseille, F-13284, France.; Aix-Marseille Université, UM 105, Marseille, F-13284, France.
Mozziconacci MJ; Centre de Recherche en Cancérologie de Marseille, (CRCM), Inserm, U1068, CNRS UMR7258, France.; Institut Paoli-Calmettes (IPC), Département d'Oncologie Moléculaire, UM 105, Marseille, F-13284, France.; IPC, Département de Biopathologie, Marseille, UM 105, Marseille, F-13284, France.
Rey J; Centre de Recherche en Cancérologie de Marseille, (CRCM), Inserm, U1068, CNRS UMR7258, France.; IPC, Département d'Hématologie, UM 105, Marseille, F-13284, France.; Aix-Marseille Université, UM 105, Marseille, F-13284, France.
Vey N; Centre de Recherche en Cancérologie de Marseille, (CRCM), Inserm, U1068, CNRS UMR7258, France.; IPC, Département d'Hématologie, UM 105, Marseille, F-13284, France.; Aix-Marseille Université, UM 105, Marseille, F-13284, France.
Chaffanet M; Centre de Recherche en Cancérologie de Marseille, (CRCM), Inserm, U1068, CNRS UMR7258, France.; Institut Paoli-Calmettes (IPC), Département d'Oncologie Moléculaire, UM 105, Marseille, F-13284, France.; Aix-Marseille Université, UM 105, Marseille, F-13284, France.
Birnbaum D; Centre de Recherche en Cancérologie de Marseille, (CRCM), Inserm, U1068, CNRS UMR7258, France.; Institut Paoli-Calmettes (IPC), Département d'Oncologie Moléculaire, UM 105, Marseille, F-13284, France.; Aix-Marseille Université, UM 105, Marseille, F-13284, France.
Murati A; Centre de Recherche en Cancérologie de Marseille, (CRCM), Inserm, U1068, CNRS UMR7258, France .; Institut Paoli-Calmettes (IPC), Département d'Oncologie Moléculaire, UM 105, Marseille, F-13284, France.; IPC, Département de Biopathologie, Marseille, UM 105, Marseille, F-13284, France.; Aix-Marseille Université, UM 105, Marseille, F-13284, France.
Pokaż więcej
Źródło :
Haematologica [Haematologica] 2017 Jan; Vol. 102 (1), pp. e11-e14. Date of Electronic Publication: 2016 Oct 14.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Genomics*
Mutation*
Cell Transformation, Neoplastic/*genetics
Hematologic Neoplasms/*genetics
Myeloproliferative Disorders/*genetics
Neoplasm Proteins/*genetics
Acute Disease ; Cell Transformation, Neoplastic/metabolism ; Cell Transformation, Neoplastic/pathology ; Chronic Disease ; Female ; Hematologic Neoplasms/metabolism ; Hematologic Neoplasms/pathology ; Humans ; Male ; Myeloproliferative Disorders/metabolism ; Myeloproliferative Disorders/pathology ; Neoplasm Proteins/metabolism
Raport
Tytuł :
Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis.
Autorzy :
Gyan E; Service d'hématologie et thérapie cellulaire, CHU de Tours, Tours, France.; Faculté de Médecine, Université François-Rabelais, UMR CNRS 7292, Tours, France.
Andrieu V; Département Hématologie et Immunologie, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris 7 University, Paris, France.
Sanna A; Unità Funzionale di Ematologia, Università degli Studi di Firenze, AOU Careggi, Florence, Italy.
Caille A; INSERM, CIC 1415, Tours, France.; Université François-Rabelais de Tours, PRES Centre-Val de Loire Université, Tours, France.; CHU de Tours, Tours, France.
Schemenau J; Department of Haematology, Oncology and Clinical Immunology, Medical Faculty, University of Düsseldorf, Düsseldorf, Germany.
Sudaka I; Laboratoire d'hématologie, CHU de Nice, Hospital Cimiez, Nice, France.
Siguret V; Hématologie biologique - Hémostase - Thrombose, Hôpital Lariboisière, INSERM UMR-S-1140, AP-HP, Paris, France.
Malet M; Service d'hématologie biologique, CHU de Caen, Caen, France.
Park S; Service d'hématologie, Centre Hospitalier Universitaire, Grenoble, France.
Bordessoule D; Service d'Hématologie, CHU Dupuytren et Faculté de Médecine, Limoges, France.
Mairesse J; Clinique Saint Pierre d'Ottignies, Service de Biopathologie, Ottignies, Belgium.
Gelsi-Boyer V; Centre de Recherches en Cancérologie, Institut Paoli-Calmettes, Marseille, France.
Cheze S; Service d'hématologie, Centre Hospitalier Universitaire, Caen, France.
Beyne-Rauzy O; Service de Médecine Interne, Centre hospitalier universitaire, Toulouse, France.
Sébert M; Service d'Hématologie clinique, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris (APHP), Paris 7 University, Paris, France.
Sapena R; Groupe Francophone des Myélodysplasies, Hôpital Saint-Louis, AP-HP, Paris, France.
Zerazhi H; Service d'onco-hématologie, Centre Hospitalier, Avignon, France.
Legros L; Service d'hématologie clinique, Centre Hospitalier Universitaire, Nice, France.
Guerci-Bresler A; Service d'hématologie CHU Brabois, Vandœuvre-lès-Nancy, France.
Amé SN; Département d'Hématologie et d'Oncologie, Centre Hospitalier Universitaire, Strasbourg, France.
Germing U; Department of Haematology, Oncology and Clinical Immunology, Medical Faculty, University of Düsseldorf, Düsseldorf, Germany.
Santini V; Unità Funzionale di Ematologia, Università degli Studi di Firenze, AOU Careggi, Florence, Italy.
Salvi F; Haematology Unit, SS. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy.
Gioia D; Fondazione Italiana Sindromi Mielodisplastiche (FISM) Onlus, Alessandria, Italy.
Lunghi M; Haematology, AOU Maggiore della Carità, Novara, Italy.
Dreyfus F; Service d'hématologie, Hôpital Cochin, AP-HP, Université Paris 5, Paris, France.
Fenaux P; Service d'Hématologie clinique, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris (APHP), Paris 7 University, Paris, France.
Pokaż więcej
Corporate Authors :
Groupe Francophone des Myélodysplasies, Fondazione Italiana per le Sindromi Mielodisplastiche (FISMonlus), and Düsseldorf MDS Registry
Źródło :
British journal of haematology [Br J Haematol] 2016 Dec; Vol. 175 (5), pp. 975-979. Date of Electronic Publication: 2016 Jan 15.
Typ publikacji :
Historical Article; Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Myelodysplastic Syndromes/*diagnosis
Neutropenia/*metabolism
Thrombocytopenia/*metabolism
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Female ; History, 21st Century ; Humans ; Male ; Middle Aged ; Myelodysplastic Syndromes/blood ; Prognosis ; World Health Organization ; Young Adult
Raport
Tytuł :
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
Autorzy :
Itzykson, R.
Kosmider, O.
Cluzeau, T.
Mansat-De Mas, V.
Beyne-Rauzy, F.
Quesnel, B.
Vey, N.
Gelsi-Boyer, V.
Raynaud, S.
Preudhomme, C.
Adès, L.
Fenaux, P.
Fontenay, M.
Beyne-Rauzy, O.
Dreyfus, F.
Pokaż więcej
Temat :
AZACITIDINE
MYELODYSPLASTIC syndromes
ACUTE myeloid leukemia
CHROMOSOMAL translocation
HUMAN cytogenetics
Źródło :
Leukemia (08876924); Jul2011, Vol. 25 Issue 7, p1147-1152, 6p, 4 Charts, 1 Graph
Czasopismo naukowe
Tytuł :
Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms.
Autorzy :
Kosmider, O.
Gelsi-Boyer, V.
Slama, L.
Dreyfus, F.
Beyne-Rauzy, O.
Quesnel, B.
Hunault-Berger, M.
Slama, B.
Vey, N.
Lacombe, C.
Solary, E.
Birnbaum, D.
Bernard, O. A.
Fontenay, M.
Pokaż więcej
Źródło :
Leukemia (08876924). May2010, Vol. 24 Issue 5, p1094-1096. 3p. 1 Chart, 1 Graph.
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies